TY - JOUR
TI - Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society
AU - Lyon, A.R.
AU - Dent, S.
AU - Stanway, S.
AU - Earl, H.
AU - Brezden-Masley, C.
AU - Cohen-Solal, A.
AU - Tocchetti, C.G.
AU - Moslehi, J.J.
AU - Groarke, J.D.
AU - Bergler-Klein, J.
AU - Khoo, V.
AU - Tan, L.L.
AU - Anker, M.S.
AU - von Haehling, S.
AU - Maack, C.
AU - Pudil, R.
AU - Barac, A.
AU - Thavendiranathan, P.
AU - Ky, B.
AU - Neilan, T.G.
AU - Belenkov, Y.
AU - Rosen, S.D.
AU - Iakobishvili, Z.
AU - Sverdlov, A.L.
AU - Hajjar, L.A.
AU - Macedo, A.V.S.
AU - Manisty, C.
AU - Ciardiello, F.
AU - Farmakis, D.
AU - de Boer, R.A.
AU - Skouri, H.
AU - Suter, T.M.
AU - Cardinale, D.
AU - Witteles, R.M.
AU - Fradley, M.G.
AU - Herrmann, J.
AU - Cornell, R.F.
AU - Wechelaker, A.
AU - Mauro, M.J.
AU - Milojkovic, D.
AU - de Lavallade, H.
AU - Ruschitzka, F.
AU - Coats, A.J.S.
AU - Seferovic, P.M.
AU - Chioncel, O.
AU - Thum, T.
AU - Bauersachs, J.
AU - Andres, M.S.
AU - Wright, D.J.
AU - López-Fernández, T.
AU - Plummer, C.
AU - Lenihan, D.
JO - European Journal of Heart Failure
PY - 2020
VL - 22
TODO - 11
SP - 1945-1960
PB - John Wiley and Sons Ltd
SN - null
TODO - 10.1002/ejhf.1920
TODO - abiraterone;  amino terminal pro brain natriuretic peptide;  atezolizumab;  avelumab;  axitinib;  bevacizumab;  binimetinib;  bortezomib;  bosutinib;  brain natriuretic peptide;  cabozantinib;  carfilzomib;  cobimetinib;  dabrafenib;  dasatinib;  daunorubicin;  dexamethasone;  doxorubicin;  durvalumab;  encorafenib;  epirubicin;  goserelin;  idarubicin;  ipilimumab;  ixazomib;  lapatinib;  lenalidomide;  lenvatinib;  leuprorelin;  neratinib;  nilotinib;  nivolumab;  pazopanib;  pembrolizumab;  pertuzumab;  pomalidomide;  ponatinib;  ramucirumab;  regorafenib;  sorafenib;  sunitinib;  tivozanib;  trametinib;  trastuzumab;  trastuzumab emtansine;  troponin;  tucatinib;  vandetanib;  vemurafenib;  antiandrogen;  antineoplastic agent, acute leukemia;  age;  androgen deprivation therapy;  ankle brachial index;  artery thrombosis;  Article;  atherosclerosis;  atherosclerotic plaque;  atrioventricular block;  breast cancer;  cancer chemotherapy;  cancer patient;  cancer radiotherapy;  cancer therapy;  cardiomyopathy;  cardiotoxicity;  cardiovascular risk;  cerebrovascular accident;  chronic kidney failure;  chronic myeloid leukemia;  colon cancer;  coronary artery bypass graft;  current smoker;  deep vein thrombosis;  diabetes mellitus;  disease risk assessment;  esophagus cancer;  estrogen receptor positive breast cancer;  fulminant myocarditis;  gastroesophageal cancer;  gastroesophageal cancer;  gastrointestinal stromal tumor;  heart amyloidosis;  heart arrhythmia;  heart atrium arrhythmia;  heart failure;  heart infarction;  heart left ventricle ejection fraction;  heart muscle ischemia;  heart muscle revascularization;  heart ventricle arrhythmia;  Hodgkin disease;  human;  human epidermal growth factor receptor 2 positive breast cancer;  human epidermal growth factor receptor 2 positive gastric cancer;  human epidermal growth factor receptor 2 positive gastric cancer;  hyperlipidemia;  hypertension;  ischemic heart disease;  kidney cancer;  kidney metastasis;  left ventricular systolic dysfunction;  liver cancer;  liver cell carcinoma;  lung embolism;  lymphoma;  melanoma;  molecularly targeted therapy;  multiple myeloma;  myeloma;  myocarditis;  non inflammatory heart failure;  non small cell lung cancer;  obesity;  ovary cancer;  percutaneous coronary intervention;  pericarditis;  peripheral occlusive artery disease;  peripheral vascular disease;  priority journal;  prostate cancer;  proteinuria;  pulmonary hypertension;  QT prolongation;  QTc interval;  sarcoma;  small cell lung cancer;  smoking;  stable angina pectoris;  stomach cancer;  thrombophilia;  thyroid cancer;  transient ischemic attack;  transitional cell carcinoma;  triple negative breast cancer;  valvular heart disease;  vasculitis;  venous thromboembolism;  aged;  cardiovascular disease;  female;  male;  middle aged;  neoplasm;  pathophysiology;  procedures;  risk assessment;  risk factor, Aged;  Androgen Antagonists;  Antineoplastic Agents;  Cardiovascular Diseases;  Female;  Heart Disease Risk Factors;  Humans;  Male;  Middle Aged;  Neoplasms;  Risk Assessment;  Risk Factors
TODO - This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies. © 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
ER -